Can Psychedelics Help PTSD, Depression, and Alzheimer’s?

Dustin Robinson joins Ryan Alford to discuss the growing body of scientific research surrounding psychedelic medicine and why mental health innovation may be entering a new era. As an attorney, investor, and advocate for responsible legal reform, Dustin explains how compounds once dismissed by society are now being studied for PTSD, depression, anxiety, and neurodegenerative diseases.

Ryan and Dustin explore FDA clinical trials, neuroplasticity, the importance of evidence-based medicine, and why responsible regulation is key to unlocking these therapies safely. They also discuss non-hallucinogenic psychedelics, Alzheimer’s research, virtual reality treatments, and how innovation could reshape the future of behavioral health.

Topics Covered

Psychedelic medicine research

PTSD and MDMA therapy

Depression and psilocybin

Neuroplasticity

Alzheimer’s and dementia

FDA clinical trials

Responsible legalization

Mental health innovation

Virtual reality therapeutics